<DOC>
	<DOCNO>NCT01138566</DOCNO>
	<brief_summary>The purpose study : 1 . To estimate prevalence extend spectrum β-lactamase ( ESBL ) and/or AmpC among Enterobacteriaceae cause community-onset urinary tract infection ( UTIs ) 2 . To collect background , risk factor clinical outcome patient community-acquired uropathogenic condition relate Enterobacteriaceae ( ESBL , AmpC- non ESBL and/or AmpC produce ) receive different antibiotic regimen . 3 . To develop score system early identify patient risk infect ESBL- and/or AmpC-producing Enterobacteriaceae compare risk factor community-onset UTIs cause ESBL- and/or AmpC-positive non ESBL -and/or AmpC Enterobacteriaceae 4 . To demonstrate efficacy safety ertapenem empiric treatment community-onset UTIs patient risk ESBL- and/or AmpC-producing organism . The study hypothesis ( ) Patients infected community-acquired uropathogenic ESBL- and/or AmpC-producing Enterobacteriaceae receive regimen carbapenems bad outcome . ( ii ) There certain risk factor predict acquisition community-onset UTIs cause ESBL- and/or AmpC-producing Enterobacteriaceae . ( iii ) The use ertapenem effective safe empirical therapy compare agent community-onset UTIs cause ESBL- and/or AmpC-producing Enterobacteriaceae .</brief_summary>
	<brief_title>Clinical Significance Optimal Treatment Community-onset Urinary Tract Infections Caused Extended-spectrum β-lactamase and/or AmpC β-lactamase Producing Enterobacteriaceae</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<criteria>Adult patient admit Taipei Veterans General Hospital diagnosis communityonset UTI cause Enterobacteriaceae eligible inclusion study hospitalization parental antimicrobial therapy require pregnancy lactation woman , history serious allergy intolerance study drug therapy ( patient history mild rash βlactams could enrol ) , complete obstruction urinary tract , perinephritic intrarenal abscess , prostatitis , rapidly progressive disease terminal illness , immunocompromising illness immuno suppression therapy , need concomitant antimicrobial addition study therapy , baseline pathogen resistant study drug , treatment systemic antimicrobial agent &gt; 24 h within 72 h prior enrolment , absolute neutrophil count &lt; 1000/mm3 . Men history physical finding suggestive acute chronic prostatitis also exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>community-onset urinary tract infection cause Enterobacteriaceae</keyword>
</DOC>